INS and diabetes mellitus: Clinical trials in diabetes patients with omega-3 PUFAs, especially DHA and EPA, have reported that hypoglycemic and antidiabetic effects of omega-3 PUFAs are derived from insulin-sensitizing actions of DHA and EPA via SREBP, PPAR, and GLP-1 production [42].